These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38091202)

  • 1. Surgery for Recurrent Epithelial Ovarian Cancer.
    Fotopoulou C; Eriksson AG; Yagel I; Chang SJ; Lim MC
    Curr Oncol Rep; 2024 Jan; 26(1):46-54. PubMed ID: 38091202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical cytoreduction for recurrent epithelial ovarian cancer.
    Al Rawahi T; Lopes AD; Bristow RE; Bryant A; Elattar A; Chattopadhyay S; Galaal K
    Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD008765. PubMed ID: 23450588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery.
    Bizzarri N; Marchetti C; Conte C; Loverro M; Giudice MT; Quagliozzi L; Distefano M; Chiantera V; Scambia G; Fagotti A
    Gynecol Oncol; 2022 Jun; 165(3):453-458. PubMed ID: 35397918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer.
    Zou R; Jiang Q; Luo X; Chen M; Yuan L; Yao L
    World J Surg Oncol; 2023 Nov; 21(1):375. PubMed ID: 38037085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
    Costales AB; Chambers L; Chichura A; Rose PG; Mahdi H; Michener CM; Yao M; Debernardo R
    J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101844. PubMed ID: 32590110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
    Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
    Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
    Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
    Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.
    van de Laar R; Zusterzeel PL; Van Gorp T; Buist MR; van Driel WJ; Gaarenstroom KN; Arts HJ; van Huisseling JC; Hermans RH; Pijnenborg JM; Schutter EM; Pelikan HM; Vollebergh JH; Engelen MJ; Inthout J; Kruitwagen RF; Massuger LF
    BMC Cancer; 2014 Jan; 14():22. PubMed ID: 24422892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of prognosis and associated factors in multiple recurrent epithelial ovarian cancer with three times or more cytoreductive surgeries].
    Zou RY; Yuan L; Chen M; Yao LQ
    Zhonghua Fu Chan Ke Za Zhi; 2023 Mar; 58(3):198-206. PubMed ID: 36935197
    [No Abstract]   [Full Text] [Related]  

  • 10. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
    Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
    J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of recurrent ovarian cancer.
    Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
    Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When should Surgery be used for Recurrent Ovarian Carcinoma?
    Bommert M; Harter P; Heitz F; du Bois A
    Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):493-497. PubMed ID: 29743148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of secondary cytoreduction surgery in platinum-resistant ovarian cancer patients within three-line recurrent: a multicenter, randomized controlled study.
    Chen T; Xu J; Xia B; Wang H; Shen Y
    J Gynecol Oncol; 2024 Jan; 35(1):e22. PubMed ID: 37945326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer.
    Pappa C; Galaal K; Smyth S; Bristow RE; Khashan AS; Alazzam M
    Cochrane Database Syst Rev; 2024 Jun; 6(6):CD015297. PubMed ID: 38934360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
    Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
    Coleman RL; Spirtos NM; Enserro D; Herzog TJ; Sabbatini P; Armstrong DK; Kim JW; Park SY; Kim BG; Nam JH; Fujiwara K; Walker JL; Casey AC; Alvarez Secord A; Rubin S; Chan JK; DiSilvestro P; Davidson SA; Cohn DE; Tewari KS; Basen-Engquist K; Huang HQ; Brady MF; Mannel RS
    N Engl J Med; 2019 Nov; 381(20):1929-1939. PubMed ID: 31722153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.
    Cecere SC; Musacchio L; Bartoletti M; Salutari V; Arenare L; Lorusso D; Ronzino G; Lauria R; Cormio G; Naglieri E; Scollo P; Marchetti C; Raspagliesi F; Greggi S; Cinieri S; Bergamini A; Orditura M; Valabrega G; Scambia G; Martinelli F; De Matteis E; Cardalesi C; Loizzi V; Perniola G; Carella C; Scandurra G; Giannone G; Pignata S
    Int J Gynecol Cancer; 2021 Jul; 31(7):1031-1036. PubMed ID: 33990353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary cytoreduction in platinum sensitive relapsed ovarian cancer: an individual patient level meta-analysis.
    Gulia S; Kannan S; Ghosh J; Rath S; Maheshwari A; Gupta S
    Int J Gynecol Cancer; 2023 Sep; 33(9):1440-1447. PubMed ID: 37567595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
    Schettino C; Musacchio L; Bartoletti M; Chiodini P; Arenare L; Baldassarre G; Califano D; Capoluongo E; Costi MP; D'Incalci M; Marchini S; Mezzanzanica D; Normanno N; Scala S; Greggi S; Perrone F; Pignata S
    Int J Gynecol Cancer; 2022 Jun; 32(6):799-803. PubMed ID: 35318277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
    Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
    Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.